In 2017, the first-in-human application of the 68Ga-labeled heterodimeric peptide BN-RGD targeting both αVβ3 integrin and GRPR for the clinical diagnostic imaging in PCa patients was introduced by Zhang et al. (2017) (Figure 5). Here, GRPR is linked to posterior cortical atrophy.